Highest-materiality recent filing
Haemonetics combines Plasma and Blood Center segments into Apheresis; Hospital renamed MedSurg
The new Apheresis segment combines formerly separate Plasma and Blood Center segments, effective Q1 FY2027.
Haemonetics announces Q4 and FY2026 results; financial details not provided in filing text
Press release issued on May 7, 2026 for quarter and fiscal year ended March 28, 2026.
Haemonetics director Charles Dockendorff will not stand for re-election at 2026 annual meeting
Charles J. Dockendorff, Board member since 2014, will not stand for re-election at the 2026 Annual Meeting.
Haemonetics repays $300M of 0.00% convertible notes at maturity
Repaid $300M principal of 0.00% Convertible Senior Notes due 2026 at maturity on March 2, 2026.
Haemonetics publishes 2024-2025 Corporate Responsibility Report
Report covers environmental, social, and governance initiatives; no financial data included.
Haemonetics reports Q3 results; specifics not available from provided text
Press release dated February 5, 2026, furnished as Exhibit 99.1 for Q3 and nine months ended December 27, 2025.
Haemonetics acquires Vivasure Medical for up to €185M; upfront €100M plus €85M earn-out
Acquired all equity of Vivasure Medical, a Galway, Ireland-based developer of percutaneous vessel closure technology.
Haemonetics announces Q2 FY2026 results; no figures in provided text
The company issued a press release on November 6, 2025 for its second quarter ended September 27, 2025.
Haemonetics reports Q1 FY2026 results; press release details not provided in filing text
Haemonetics issued press release on Aug 7, 2025 for Q1 ended June 28, 2025.
All nine nominees elected with 42.6-43.8M votes; broker non-votes 1.76M.
Haemonetics approves restructuring $20M charges; targets $30M annual savings
Board approved market and regional alignment initiative in May 2025.
Haemonetics appoints Frank Chan as EVP COO, promotes Roy Galvin to CCO
Frank Chan appointed EVP COO effective April 7, 2025; oversees R&D, regulatory, global manufacturing & supply chain.
Haemonetics issues Q3 FY2025 earnings press release; no details available in input
Filing reports results for Q3 and nine months ended December 28, 2024, via press release.
Haemonetics completes sale of whole blood assets to GVS for up to $67.8M
Total cash consideration up to $67.8M: $45.3M upfront (adjusted) plus up to $22.5M contingent.
Haemonetics EVP Global Manufacturing to retire July 11, 2025
Josep Llorens, EVP Global Manufacturing and Supply Chain, notified retirement effective July 11, 2025.
Haemonetics sells whole blood assets to GVS for $44.6M cash plus up to $22.5M earnout
Total consideration up to $67.1M: $44.6M cash at close plus up to $22.5M contingent on sales growth and milestones.
Haemonetics announces Q2 FY2025 results; specific figures unavailable from provided filing text
Company issued press release for quarter ended Sept 28, 2024 and first half of fiscal 2025.
Haemonetics CTO Anila Lingamneni to depart on November 1, 2024
Anila Lingamneni, EVP and Chief Technology Officer, will leave Haemonetics effective November 1, 2024.
Haemonetics reports Q1 FY2025 results; details in press release not provided
Filed 8-K on August 8, 2024 for quarter ended June 29, 2024.
Haemonetics shareholders elect directors, approve executive pay and auditor at 2024 annual meeting
All 9 director nominees elected with ~47.1M–47.6M votes each; no director received less than 46.8M for.
All nine Haemonetics directors elected; say-on-pay and auditor ratification pass
Quorum of 95.99% (48.9M of 50.95M shares) represented at the July 25, 2024 annual meeting.
Issued $700M (incl. $100M greenshoe) of 2.50% Convertible Senior Notes due June 1, 2029.
Haemonetics prices $600M 2.50% convertible notes due 2029; to repurchase $200M of 2026 notes
$600M 2.50% convertible senior notes due 2029 priced; initial conversion price ~$117.12/share (30% premium over $90.09 closing).
Haemonetics announces $525M convertible senior notes offering due 2029
$525M principal amount of convertible senior notes due 2029, with option for additional $75M.
Haemonetics announces Q4 and FY2024 financial results; details not available in this filing
Press release dated May 9, 2024, reports results for quarter and fiscal year ended March 30, 2024.
Haemonetics enters $1B credit agreement; $250M term loan, $750M revolver due 2029
New $250M senior unsecured term loan retires existing term loan under 2022 credit agreement.
Haemonetics completes acquisition of Attune Medical (Advanced Cooling Therapy)
Acquisition closed on April 1, 2024; terms consistent with March 5, 2024 8-K disclosure.
Haemonetics to acquire Attune Medical for $160M upfront; device complements EP portfolio
Upfront cash $160M plus contingent consideration based on sales growth and milestones.
Haemonetics reports Q3 FY2024 results; specific figures not available in provided text
Filed an 8-K on Feb 8, 2024, announcing Q3 and nine-month results for period ended Dec 30, 2023.
Haemonetics closes acquisition of OpSens Inc.
Acquisition of OpSens Inc. closed on December 12, 2023, as previously announced.
Haemonetics reports Q2 FY2024 results; specific figures not included in filed document
Earnings release dated November 2, 2023 for quarter and first half ended September 30, 2023.
Haemonetics to acquire OpSens for $2.90/share cash via arrangement
Haemonetics to acquire all outstanding shares of OpSens via plan of arrangement under Quebec Business Corporations Act.
Haemonetics to acquire OpSens for CAD $2.90/share in cash, expected close by March 31, 2024
Haemonetics (HAE) will pay CAD $2.90 per share for all OpSens common shares via a plan of arrangement under Québec law.
Haemonetics Q1 fiscal 2024 results announced; press release text not available
Filing states Haemonetics issued a press release on Aug 8, 2023 for Q1 ended July 1, 2023.
Haemonetics elects Diane M. Bryant to board, shareholders approve amended LTIP with 2.97M new shares
Diane M. Bryant elected to board effective 8/4/2023; former CEO of NovaSignal, ex-COO of Google Cloud, 32-year Intel veteran.
Haemonetics reports Q4 and FY2023 results; specific figures not available
Reported financial results for quarter and fiscal year ended April 1, 2023.
Haemonetics Q3 fiscal 2023 adjusted EPS $0.82, revenue $298.1M; raises full-year guidance
Q3 revenue $298.1M (+2.1% reported, -0.1% organic); GAAP EPS $0.37, adjusted EPS $0.82 vs $0.73 prior year.
Haemonetics files 8-K for Q2 FY2023 results; filing lacks specific financial figures
Company issued press release for Q2 ended October 1, 2022 and first half FY2023 results.
Haemonetics appoints Maryanne Farris as VP, Chief Accounting Officer; GC Michelle Basil continues
Maryanne Farris joined as VP, Chief Accounting Officer and principal accounting officer on Oct 17, 2022.
Haemonetics reports Q1 FY2023 earnings; no financial details in filing excerpt
Press release dated August 10, 2022, covering quarter ended July 2, 2022, was furnished as exhibit.
James C. D'Arecca, EVP/CFO, assumes principal accounting officer role effective Aug 5, 2022, replacing departing controller Dan Goldstein.
New $420M revolving credit facility (up from $350M) and $280M term loan to replace existing term loan.
EVP & General Counsel Michelle Basil to depart Haemonetics by Oct 31, 2022
Michelle L. Basil, EVP and General Counsel, will transition from Haemonetics effective October 31, 2022.
Haemonetics principal accounting officer Dan Goldstein to depart Aug 9, 2022
Dan Goldstein, VP Corporate Controller and Principal Accounting Officer, will leave on August 9, 2022.
Haemonetics issues Q4 FY2022 earnings press release; details not available in filing text
Press release dated May 10, 2022, furnished as Exhibit 99.1, covers Q4 and full year ended April 2, 2022.
Haemonetics appoints James D'Arecca as CFO effective April 11, 2022; Burke to retire
James D'Arecca appointed CFO effective April 11, 2022; William Burke steps down as CFO on that date.
President of Global Plasma and Blood Center Chad Nikel to leave Haemonetics on March 2, 2022
Chad Nikel, President of Global Plasma and Blood Center, will depart Haemonetics effective March 2, 2022.
Haemonetics announces Q3 FY2022 results; no figures in filing text
Filing reports Q3 and nine-month results for period ended Jan 1, 2022.
Haemonetics CFO Burke to retire June 2022; retention bonus up to 50% of base salary
CFO William P. Burke to retire in June 2022; will remain in role and assist transition until then.
Haemonetics reports Q1 FY2022 results; details not available in filing excerpt
Filed 8-K on Aug 11, 2021 for Q1 ended July 3, 2021 results.
On April 27, 2026, Charles J. Dockendorff informed Haemonetics Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”).
On March 3, 2025, Haemonetics Corporation (the “Company”) announced the appointment of Frank W. Chan, Ph.D. as its Executive Vice President, Chief Operating Officer, effective April 7, 2025.
Josep Llorens, Executive Vice President, Global Manufacturing and Supply Chain, has notified Haemonetics Corporation (the “Company”) of his decision to retire from the Company effective July 11, 2025.
Anila Lingamneni, Executive Vice President, Chief Technology Officer, will leave Haemonetics Corporation (the “Company”) on November 1, 2024.
On August 4, 2023, the Board of Directors of Haemonetics Corporation (the “Company”) elected Diane M. Bryant as a director of the Company, effective immediately.
Ms. Farris, age 47, joined the Company as Vice President, Chief Accounting Officer on October 17, 2022.
On August 5, 2022, the Board of Directors of Haemonetics Corporation (the “Company”) appointed James C. D’Arecca, Executive Vice President, Chief Financial Officer, as the Company’s principal accounting officer
On June 16, 2022, Haemonetics Corporation (the “Company”) announced that Michelle L. Basil, Executive Vice President, General Counsel has decided to transition from the Company effective October 31, 2022.
Dan Goldstein, Vice President, Corporate Controller and Principal Accounting Officer will leave Haemonetics Corporation (the “Company”) on August 9, 2022.
On March 21, 2022, the Company announced the appointment of James C. D’Arecca as its Chief Financial Officer, effective April 11, 2022.
Mr. Burke will step down as Chief Financial Officer and principal financial officer of the Company on April 11, 2022
William P. Burke, Executive Vice President, Chief Financial Officer (“CFO”) has decided to retire from the Company in June 2022.
Max materiality 0.75 · Median 0.40 · Most common event earnings